On Thursday, Piper Sandler exhibited confidence in shares of Oscar Health Inc (NYSE:OSCR) by increasing the company's price target from $25.00 to $28.00, while retaining an Overweight rating on the stock. This decision follows Oscar Health's impressive performance in the second quarter of 2024, which surpassed both Piper Sandler's and consensus estimates in terms of growth and profitability.
The company's strong results in the first half of 2024 have led Oscar Health to revise its full-year 2024 revenue and adjusted EBITDA guidance upwards. Specifically, the revenue guidance for the calendar year 2024 has been increased by 8.4% at the midpoint, and the guidance for adjusted EBITDA has seen a 23.3% hike at the midpoint.
The upbeat performance in the second quarter is a testament to the company's momentum, which has been building throughout the first half of the year. Given these positive developments, Piper Sandler has reiterated its Overweight rating on the stock.
The new price target of $28.00 is based on a steady 15x multiple of the higher projected adjusted EBITDA for the calendar year 2025. This adjustment reflects a more optimistic outlook for Oscar Health's financial trajectory in the coming year.
Investors and market watchers will likely keep a close eye on Oscar Health as it continues to navigate the competitive health insurance industry, bolstered by its recent successes and revised financial forecasts.
In other recent news, Oscar Health reported a significant increase in its second-quarter revenue, which reached $2.2 billion, marking a 46% year-over-year growth. The company's medical loss ratio improved, and adjusted EBITDA also saw a substantial rise. Furthermore, Oscar Health has increased its full-year 2024 revenue and adjusted EBITDA guidance, attributing this to growth in membership.
The company's strategic focus on increasing its market presence and diversifying growth through the Individual Coverage Health Reimbursement Arrangement (ICRA) business is central to its long-term financial goals. Oscar Health's confidence is reflected in its raised revenue guidance for 2024 by $700 million. Despite expecting an increase in the medical loss ratio for the full year, the company remains optimistic about achieving total company adjusted EBITDA profitability this year.
Oscar Health's recent developments underscore its financial strength and strategic initiatives aimed at long-term growth. The company's focus on expanding its market presence and capitalizing on the ICRA business reflects its commitment to innovation and growth in the health insurance sector. Oscar Health's bullish outlook, backed by robust capital reserves and a clear strategic vision, indicates a confident path forward.
InvestingPro Insights
Following Piper Sandler's positive outlook on Oscar Health Inc (NYSE:OSCR), current metrics from InvestingPro show a nuanced picture that investors may find valuable. Despite not paying dividends, Oscar Health has demonstrated a significant year-to-date price total return of 82.51%, highlighting the stock's strong performance in the market. However, it is important to note that the company's price has experienced volatility, with a 19.48% decline over the last three months, reflecting some investor caution amid its growth.
The company's revenue growth remains robust, with a 45.13% increase over the last twelve months as of Q2 2024, indicating a solid expansion in its business operations. This aligns with the optimistic revenue guidance revision provided by Oscar Health.
Yet, the InvestingPro Tips suggest that the stock is trading at a high earnings multiple and suffers from weak gross profit margins, which currently stand at 22.12%. Moreover, analysts do not anticipate Oscar Health to be profitable this year, which may temper some expectations despite the high return over the last year.
Investors considering Oscar Health as part of their portfolio can find additional insights and tips on InvestingPro, with a total of 7 more tips available to help make informed decisions. The current fair value estimations range from $18.84 by InvestingPro to $28.00 by analysts, suggesting a potential upside based on current price levels. For detailed analysis and further tips, visit https://www.investing.com/pro/OSCR.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.